Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas, Adrian Segura Diaz, Regina García Delgado, Alberto Alvarez-Larran, María Alicia Senin, Elvira Mora, Maria Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente Alegre, Míriam Vara, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Maria Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, María José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2024-200698

Published: 2024

Journal Articles

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Blood (2024) 144 (Supplement 1): 241.

https://doi.org/10.1182/blood-2024-198336

Published: 2024

Journal Articles

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 4549.

https://doi.org/10.1182/blood-2024-205800

Published: 2024

Journal Articles

REVEAL puts leukocytes into risk stratification

Alberto Alvarez-Larrán

Blood (2024) 143 (16): 1561–1562.

https://doi.org/10.1182/blood.2023023580

Published: 2024

Journal Articles

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Blood (2023) 142 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2023-188875

Published: 2023

Journal Articles

Utility of Assessing Primary Hemostasis By Determining Platelet Function and Von Willebrand Factor in Patients with Myeloproliferative Neoplasms

Meritxell Nomdedeu, Ana Belén Moreno Castaño, Marta Garrote, Eduardo Arellano-Rodrigo, Sara Carbonell-Ordeig, Blanca de Moner, Ginés Escolar, Jordi Esteve, Dolors Tassies, Maribel Diaz-Ricart, Joan Carles Reverter, Alberto Alvarez-Larran

Blood (2023) 142 (Supplement 1): 6405.

https://doi.org/10.1182/blood-2023-186987

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model

Ernesto J Cuenca, Pedro J Guijarro-Carrillo, María J López-Poveda, Paula Durán-Espin, Eva Soler, María Luz Morales, Maria Luisa Lozano, Alberto Alvarez-Larran, Nuria Garcia-Barbera, Rocio Gonzalez-Conejero, Constantino Martínez, Raul Teruel Montoya, Francisca Ferrer Marin

Blood (2022) 140 (Supplement 1): 9598–9599.

https://doi.org/10.1182/blood-2022-156886

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi

Blood (2022) 140 (Supplement 1): 6815–6818.

https://doi.org/10.1182/blood-2022-158902

Published: 2022

Journal Articles

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Blood (2022) 140 (Supplement 1): 826–827.

https://doi.org/10.1182/blood-2022-158669

Published: 2022

Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Blood (2022) 140 (Supplement 1): 1504–1506.

https://doi.org/10.1182/blood-2022-162207

Published: 2022

Journal Articles

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 12245–12247.

https://doi.org/10.1182/blood-2022-168900

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Low-Risk Polycythemia Vera Treated with Phlebotomies: Clinical Characteristics, Hematologic Control and Complications in 358 Patients from the Spanish Registry of Polycythemia Vera

Blood (2021) 138 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2021-145012

Published: 2021

Journal Articles

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Rosa Ayala, Rafael Alonso Fernández, Valentín Garcia Gutierrez, Alberto Alvarez-Larran, Santiago Osorio, Jose M. Sanchez, Gonzalo Carreño Gomez-Tarragona, María Teresa Gómez-Casares, Antonia Duran, Joaquín Martínez-López

Blood (2021) 138 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2021-150240

Published: 2021

Journal Articles

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Sarit Assouline, Maria Cristina Miggiano, Elisabetta Abruzzese, Chiara Elena, Giovanni Caocci, Susanne Saussele, Francesca Lunghi, Alberto Alvarez-Larran, Barbara Mora, Sigi Petrela, Laura Antolini, Carlo Gambacorti-Passerini, Alessandra Iurlo

Blood (2021) 138 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2021-150496

Published: 2021

NARROW

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

REVEAL puts leukocytes into risk stratification

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Utility of Assessing Primary Hemostasis By Determining Platelet Function and Von Willebrand Factor in Patients with Myeloproliferative Neoplasms

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Low-Risk Polycythemia Vera Treated with Phlebotomies: Clinical Characteristics, Hematologic Control and Complications in 358 Patients from the Spanish Registry of Polycythemia Vera

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only